Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.

Product information

CAS Number: 99464-64-9

Molecular Weight: 447.46

Formula: C20H21N3O7S

Synonym:

CP 65703

Flucam

Chemical Name: ethyl 1-({2-methyl-1,1-dioxo-3-[(pyridin-2-yl)carbamoyl]-2H-1,2-benzothiazin-4-yl}oxy)ethyl carbonate

Smiles: CCOC(=O)OC(C)OC1=C(C(=O)NC2=CC=CC=N2)N(C)S(=O)(=O)C2=CC=CC=C21

InChiKey: LSNWBKACGXCGAJ-UHFFFAOYSA-N

InChi: InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 90 mg/mL(201.13 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. [1] Ampiroxicam (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. Ampiroxicam (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells. [2]

In Vivo:

Ampiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. Ampiroxicam inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. Ampiroxicam blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. Ampiroxicam (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats. [3] Ultraviolet-A (UVA)-irradiated 1% Ampiroxicam sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% Ampiroxicam and 1% thiosalicylate (TOS). Concentration of Ampiroxicam is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam. [4]

References:

1. Carty TJ, et al. Agents Actions, 1993, 39(3-4), 157-165.
2. Abdelrahim M, et al. Cancer Res, 2007, 67(7), 3286-3294.
3. Abdelrahim M, et al. J Natl Cancer Inst, 2006, 98(12), 855-868.
4. Sasaki T, et al. J Dermatol Sci, 1999, 21(3), 170-175.

Products are for research use only. Not for human use.